Handelsavisen
prelaunch
Companies ›Healthcare ›ORKA.O
OR
ORKA.O — NASDAQ Biotechnology

Orka.O

$94,79
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,4B USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-14,4 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$97,86
Open
$90,32
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Oruka Therapeutics Inc operates as a biotechnology company within the Health Care sector, currently generating no revenue while incurring operating losses consistent with pre-commercial clinical development stages.

Business. Oruka Therapeutics Inc operates as a biotechnology company within the Health Care sector, currently generating no revenue while incurring operating losses consistent with pre-commercial clinical development stages.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY14 analysts
14 buy0 hold0 sell
Avg 12m price target146,85

Analyst recommendations

14 analysts · consensus Buy
Buy14
Hold0
Sell0
12-month price target
146,85
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
14 analysts · indicative
Ownership→
FMR LLC
largest disclosed fund holder
Profitability→
-14,4 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ORKA.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ORKA.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Oruka Therapeutics Inc operates as a biotechnology company within the Health Care sector, currently generating no revenue while incurring operating losses consistent with pre-commercial clinical development stages.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    The company maintains a pristine balance sheet with total assets of $37.86 million, composed almost entirely of $37.43 million in cash and equivalents. Total liabilities are minimal at $0.84 million, resulting in a debt-to-equity ratio of 0.0 and a current ratio that implies strong short-term solvency. The market capitalization stands at $1.43 billion, driven by a price-to-book ratio of 38.72, reflecting significant investor expectations for future value creation despite the absence of tangible earnings.

    Profitability metrics are negative, with a net income of -$5.34 million and an operating income of -$7.29 million for the latest period. Return on equity is -14.42% and return on assets is -14.10%, indicating that the company is consuming capital to fund operations. The EV/EBITDA ratio is negative, which is standard for pre-revenue biotechnology firms that have not yet achieved profitability or positive cash flow from operations.

    Revenue is reported as $0.0, confirming the company is in a pre-commercial phase with no current product sales. Without segment or geographic data, the revenue mix cannot be analyzed, but the zero revenue figure suggests all activities are focused on research, development, and clinical trials rather than commercial distribution.

    Growth trajectory cannot be assessed via historical revenue trends as the company has no revenue history. The operating cash flow is negative at -$5.01 million, consistent with the burn rate required for biotechnology R&D. Capital expenditure is reported as $0.0, suggesting that cash outflows are primarily directed toward operating expenses such as personnel and clinical trial costs rather than fixed asset acquisition.

    Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The company’s primary risk lies in its pre-revenue status and the binary nature of biotechnology development, where failure in clinical trials can significantly impact valuation. The low dilution risk suggests that the current share count of 14.5 million is stable, with no immediate pressure from equity issuances.

    Recent observations include strong analyst sentiment, with a mean recommendation of 1.50 (strong buy) and a mean price target of $146.85, implying significant upside from the current market price of $98.84. There are 7 strong buy and 7 buy ratings, with no hold ratings, indicating high conviction among covering analysts. No specific news events or filing observations were provided beyond the reconciler enqueue logs, which are internal system events and not material business developments.

    Key takeaways
    • Oruka Therapeutics is a pre-revenue biotechnology firm with $37.43 million in cash and no debt.
    • The company reported a net loss of $5.34 million and negative operating cash flow of $5.01 million.
    • Valuation is high at a P/B of 38.72, reflecting growth expectations rather than current fundamentals.
    • Analyst sentiment is overwhelmingly positive with a mean price target of $146.85 vs. current price of $98.84.
    • Dilution and liquidity risks are assessed as low, with a stable share count of 14.5 million.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-13
    Q1 2026 · Quarter highlights
    Open report →

    Operating income −45,2% YoY; Net income −51,5% YoY.

    Revenue—
    Operating income-$36.4M−45,2 % YoY
    Net income-$31.8M−51,5 % YoY
    Free cash flow-$31.9M−51,7 % YoY
    EPS—
    Operating cash flow-$23.6M−13,0 % YoY
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income-$36.4M
    Net income-$31.8M
    Balance sheet
    Total assets$504.5M
    Total liabilities$17.8M
    Total equity$486.7M
    Cash & equivalents$49.5M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$23.6M
    CapEx-$73.0k
    Free cash flow-$31.9M
    SBC—
    Highlights
    • ▍Operating income −45,2% YoY
    • ▍Net income −51,5% YoY
    • ▍Free cash flow −51,7% YoY

    Valuation TTM

    Market price
    $94,79
    Market cap
    $1.43B
    Enterprise valueⓘ
    $1.40B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    38.7x
    P / Tangible bookⓘ
    38.7x
    Tangible book
    $37.0M
    Net cashⓘ
    $37.4M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    -14.1%
    ROEⓘ
    -14.4%
    Cash conversionⓘ
    94.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 41 %
    EPS
    Consensus EPS
    -2,07
    Predicted surprise
    -0,01
    Beat probability
    41 %
    Analysts
    14
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-07-31 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-2,07
    Revenue—no estimate—no estimate0 USD
    Operating income—no estimate—no estimate-159,7M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution14 analysts
    Strong buy7
    Buy7
    Hold0
    Sell0
    Strong sell0
    12-month price target$146,85 · Median $150,00
    Low $102,00High $200,00
    Operating income · consensus-159,7M USD
    EPS surprise
    +10,5 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$102,00
    Mean$146,85
    Median$150,00
    High$200,00
    Spot$94,79
    +54.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-14,4 %Above median
    D/E0,00Above median
    Cash Conv0,94Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 3 524 281 sh24 exercises · 6 grants8 insiders
    • Goncalves JoanaChief Medical Officer · Employee Stock Option (right to buy) → Common StockDisposed 3 500 @ $6,84exercise · 2026-07-15
    • Goncalves JoanaChief Medical Officer · Employee Warrant (right to buy) → Common StockDisposed 3 500 @ $7,80exercise · 2026-07-15
    • Agarwal ArjunSenior Vice President, Finance · Employee Stock Option (right to buy) → Common StockDisposed 8 541 @ $12,50exercise · 2026-07-13
    • Agarwal ArjunSenior Vice President, Finance · Employee Stock Option (right to buy) → Common StockDisposed 1 458 @ $34,39exercise · 2026-07-13
    • Sandler Laura LeeChief Operating Officer · Employee Warrant (right to buy) → Common StockDisposed 5 000 @ $7,80exercise · 2026-07-01
    • Fairmount Funds Management LLCDirector, 10% owner · Series B Preferred Stock → Common StockDisposed 3 553 410conversion · 2026-07-01
    • Goncalves JoanaChief Medical Officer · Employee Warrant (right to buy) → Common StockDisposed 3 500 @ $7,80exercise · 2026-06-15
    • Goncalves JoanaChief Medical Officer · Employee Stock Option (right to buy) → Common StockDisposed 3 500 @ $6,84exercise · 2026-06-15
    • Agarwal ArjunSenior Vice President, Finance · Employee Stock Option (right to buy) → Common StockDisposed 8 000 @ $12,50exercise · 2026-06-12
    • Agarwal ArjunSenior Vice President, Finance · Employee Stock Option (right to buy) → Common StockDisposed 1 459 @ $34,39exercise · 2026-06-12
    • BALL KRISTINE MDirector · Stock Option (right to buy) → Common StockAcquired 9 136 @ $55,23grant · 2026-06-02
    • Dambkowski CarlDirector · Stock Option (right to buy) → Common StockAcquired 9 136 @ $55,23grant · 2026-06-02
    • Fairmount Funds Management LLCDirector, 10% owner · Stock Option (Right to Buy) → Common StockAcquired 9 136 @ $55,23grant · 2026-06-02
    • Kulkarni SamarthDirector · Stock Option (right to buy) → Common StockAcquired 9 136 @ $55,23grant · 2026-06-02
    • Martin Christopher NathanDirector · Stock Option (right to buy) → Common StockAcquired 9 136 @ $55,23grant · 2026-06-02
    • Dambkowski CarlDirector · Warrant (right to buy) → Common StockDisposed 11 904 @ $7,80exercise · 2026-05-21
    • Dambkowski CarlDirector · Stock Option (right to buy) → Common StockDisposed 11 667 @ $11,77exercise · 2026-05-21
    • Dambkowski CarlDirector · Stock Option (right to buy) → Common StockDisposed 38 689 @ $6,84exercise · 2026-05-21
    • Agarwal ArjunSenior Vice President, Finance · Employee Stock Option (right to buy) → Common StockDisposed 5 833 @ $34,39exercise · 2026-05-18
    • Agarwal ArjunSenior Vice President, Finance · Employee Stock Option (right to buy) → Common StockDisposed 2 000 @ $12,50exercise · 2026-05-18
    • Goncalves JoanaChief Medical Officer · Employee Warrant (right to buy) → Common StockDisposed 3 500 @ $7,80exercise · 2026-05-15
    • Goncalves JoanaChief Medical Officer · Employee Stock Option (right to buy) → Common StockDisposed 3 500 @ $6,84exercise · 2026-05-15
    • Sandler Laura LeeChief Operating Officer · Employee Warrant (right to buy) → Common StockDisposed 5 000 @ $7,80exercise · 2026-05-01
    • Goncalves JoanaChief Medical Officer · Employee Stock Option (right to buy) → Common StockDisposed 3 500 @ $6,84exercise · 2026-04-15
    • Goncalves JoanaChief Medical Officer · Employee Warrant (right to buy) → Common StockDisposed 3 500 @ $7,80exercise · 2026-04-15

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • Oruka Therapeutics, Inc. Market data — financials · 2026-07-31
    • reconciler_enqueue (reconciler) on ORKA.O · 2026-07-31
    • Oruka Therapeutics Inc Market data — analyst estimates · 2026-07-31
    • Oruka Therapeutics Inc Market data — ESG · 2026-07-31

    Ownership & reference

    Top holders

    • FMR LLCInstitutional Investor · as of 2026-03-310,02 %$365M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,01 %$49M
    • Jennison Associates LLCInvestment Managers · as of 2026-03-310,01 %$9M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$47M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$79M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$16M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$15M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$4M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$10M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$12M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$6M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$6M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$74M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$5M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$5M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$9M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Lawrence Otto KleinPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 58 sellsnet -$314,8M7 insiders · last 365d
    • Goncalves JoanaChief Medical Officer · Common StockOther 3 500 @ $6,84$24K · 2026-07-15
    • Goncalves JoanaChief Medical Officer · Common StockSold 300 @ $87,25$26K · 2026-07-15
    • Goncalves JoanaChief Medical Officer · Common StockSold 3 803 @ $86,68$330K · 2026-07-15
    • Goncalves JoanaChief Medical Officer · Common StockSold 2 497 @ $85,86$214K · 2026-07-15
    • Goncalves JoanaChief Medical Officer · Common StockOther 3 500 @ $7,80$27K · 2026-07-15
    • Goncalves JoanaChief Medical Officer · Common StockSold 400 @ $84,36$34K · 2026-07-15
    • Agarwal ArjunSenior Vice President, Finance · Common StockSold 300 @ $85,63$26K · 2026-07-13
    • Agarwal ArjunSenior Vice President, Finance · Common StockOther 8 541 @ $12,50$107K · 2026-07-13
    • Agarwal ArjunSenior Vice President, Finance · Common StockOther 1 458 @ $34,39$50K · 2026-07-13
    • Agarwal ArjunSenior Vice President, Finance · Common StockSold 300 @ $83,07$25K · 2026-07-13
    • Agarwal ArjunSenior Vice President, Finance · Common StockSold 3 743 @ $84,26$315K · 2026-07-13
    • Agarwal ArjunSenior Vice President, Finance · Common StockSold 5 656 @ $84,90$480K · 2026-07-13
    • Sandler Laura LeeChief Operating Officer · Common StockSold 500 @ $95,47$48K · 2026-07-01
    • Fairmount Funds Management LLCDirector, 10% owner · Common StockOther 3 553 410 · 2026-07-01
    • Fairmount Funds Management LLCDirector, 10% owner · Common StockSold 3 553 410 @ $84,43$300,0M · 2026-07-01
    • Sandler Laura LeeChief Operating Officer · Common StockOther 5 000 @ $7,80$39K · 2026-07-01
    • Sandler Laura LeeChief Operating Officer · Common StockSold 2 237 @ $93,85$210K · 2026-07-01
    • Sandler Laura LeeChief Operating Officer · Common StockSold 2 263 @ $94,75$214K · 2026-07-01
    • Agarwal ArjunSenior Vice President, Finance · Common StockSold 699 @ $82,14$57K · 2026-06-22
    • Agarwal ArjunSenior Vice President, Finance · Common StockSold 888 @ $80,01$71K · 2026-06-22
    • Klein Lawrence OttoDirector, Chief Executive Officer · Common StockSold 1 729 @ $69,69$120K · 2026-06-15
    • Agarwal ArjunSenior Vice President, Finance · Common StockSold 395 @ $69,69$28K · 2026-06-15
    • Goncalves JoanaChief Medical Officer · Common StockOther 3 500 @ $7,80$27K · 2026-06-15
    • Goncalves JoanaChief Medical Officer · Common StockOther 3 500 @ $6,84$24K · 2026-06-15
    • Goncalves JoanaChief Medical Officer · Common StockSold 1 636 @ $68,38$112K · 2026-06-15

    Short positioning

    8.8Mshares short-3.6% vs prior
    6.24days to cover
    59.9%short of daily vol
    116fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ORKA.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob41 %Surprise-0,01Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Current liabilities (annual): USD 15.37MUnknown
    • Cash & equivalents (annual): USD 46.94MUnknown
    • Operating income (annual): USD -122.05MUnknown
    • Operating cash flow (annual): USD -88.21MUnknown
    • Net income (annual): USD -105.43MUnknown
    • Total operating expenses (annual): USD 122.05MUnknown
    • Shares outstanding (annual): 48.72MUnknown
    • Total liabilities (annual): USD 16.69MUnknown
    • Shareholders' equity (annual): USD 471.93MUnknown
    • Current assets (annual): USD 343.86MUnknown
    • Pre-tax income (annual): USD -105.43MUnknown
    • Total assets (annual): USD 488.62MUnknown
    • R&D expense (annual): USD 100.64MUnknown
    • Capex (annual): USD 209KUnknown
    • R&D expense (annual): USD 75.06MUnknown
    • Shares outstanding (annual): 37.44MUnknown
    • Current liabilities (annual): USD 13.04MUnknown
    • Cash & equivalents (annual): USD 61.58MUnknown
    • Operating income (annual): USD -88.12MUnknown
    • Net income (annual): USD -83.72MUnknown
    • Operating cash flow (annual): USD -57.84MUnknown
    • Capex (annual): USD 189KUnknown
    • Current assets (annual): USD 376.87MUnknown
    • Total assets (annual): USD 396.02MUnknown
    Showing 24 of 30 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-15INSIDERGoncalves Joana transacted 3.5k sh — Chief Medical Officer ~$24k
    2026-07-15INSIDERGoncalves Joana sold 300 sh — Chief Medical Officer ~$26k
    2026-07-15INSIDERGoncalves Joana sold 3.8k sh — Chief Medical Officer ~$330k
    2026-07-15INSIDERGoncalves Joana sold 2.5k sh — Chief Medical Officer ~$214k
    2026-07-15INSIDERGoncalves Joana sold 400 sh — Chief Medical Officer ~$34k
    2026-07-15INSIDERGoncalves Joana disposed of 3.5k sh Employee Warrant (right to buy) — Chief Medical Officer
    2026-07-13INSIDERAgarwal Arjun sold 300 sh — Senior Vice President, Finance ~$26k
    2026-07-13INSIDERAgarwal Arjun transacted 8.5k sh — Senior Vice President, Finance ~$107k
    2026-07-13INSIDERAgarwal Arjun transacted 1.5k sh — Senior Vice President, Finance ~$50k
    2026-07-13INSIDERAgarwal Arjun sold 3.7k sh — Senior Vice President, Finance ~$315k
    2026-07-13INSIDERAgarwal Arjun sold 5.7k sh — Senior Vice President, Finance ~$480k
    2026-07-13INSIDERAgarwal Arjun disposed of 8.5k sh Employee Stock Option (right to buy) — Senior Vice President, Finance
    2026-07-13INSIDERAgarwal Arjun disposed of 1.5k sh Employee Stock Option (right to buy) — Senior Vice President, Finance
    2026-07-01INSIDERSandler Laura Lee sold 500 sh — Chief Operating Officer ~$48k
    2026-07-01INSIDERFairmount Funds Management LLC transacted 3.55M sh — Director, 10% owner
    2026-07-01INSIDERFairmount Funds Management LLC sold 3.55M sh — Director, 10% owner ~$300.01M
    2026-07-01INSIDERSandler Laura Lee transacted 5.0k sh — Chief Operating Officer ~$39k
    2026-07-01INSIDERSandler Laura Lee sold 2.2k sh — Chief Operating Officer ~$210k
    2026-07-01INSIDERSandler Laura Lee sold 2.3k sh — Chief Operating Officer ~$214k
    2026-07-01INSIDERFairmount Funds Management LLC disposed of 42.6k sh Series B Preferred Stock — Director, 10% owner
    2026-07-01INSIDERSandler Laura Lee disposed of 5.0k sh Employee Warrant (right to buy) — Chief Operating Officer
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-22 00:00 UTCINSIDER28 insider transactions — 2026-06 · net sell $3.8M 9 derivative
    2026-06-22 00:00 UTCINSIDER28 insider transactions — 2026-06 · net sell $3.8M 9 derivative
    2026-06-22INSIDERAgarwal Arjun sold 699 sh — Senior Vice President, Finance ~$57k
    2026-06-22INSIDERAgarwal Arjun sold 888 sh — Senior Vice President, Finance ~$71k
    2026-06-15INSIDERKlein Lawrence Otto sold 1.7k sh — Director, Chief Executive Officer ~$120k
    2026-06-15INSIDERAgarwal Arjun sold 395 sh — Senior Vice President, Finance ~$28k
    2026-06-15INSIDERGoncalves Joana transacted 3.5k sh — Chief Medical Officer ~$27k
    2026-06-15INSIDERGoncalves Joana sold 1.6k sh — Chief Medical Officer ~$112k
    2026-06-15INSIDERGoncalves Joana disposed of 3.5k sh Employee Stock Option (right to buy) — Chief Medical Officer
    2026-06-12INSIDERAgarwal Arjun disposed of 1.5k sh Employee Stock Option (right to buy) — Senior Vice President, Finance
    2026-06-12INSIDERAgarwal Arjun disposed of 8.0k sh Employee Stock Option (right to buy) — Senior Vice President, Finance
    2026-06-04FILINGCURRENT REPORT →
    2026-06-02INSIDERDambkowski Carl acquired 9.1k sh Stock Option (right to buy) — Director
    2026-06-02INSIDERKulkarni Samarth acquired 9.1k sh Stock Option (right to buy) — Director
    2026-06-02INSIDERMartin Christopher Nathan acquired 9.1k sh Stock Option (right to buy) — Director
    2026-06-02INSIDERBALL KRISTINE M acquired 9.1k sh Stock Option (right to buy) — Director
    2026-06-02INSIDERFairmount Funds Management LLC acquired 9.1k sh Stock Option (Right to Buy) — Director, 10% owner
    Showing the 40 most recent of 66 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage